Regulatory and cost implications for switching injectable delivery formats

Since there are various options for injectable formats, it’s not an uncommon practice to launch a large molecule in one format and then later decide to switch the delivery format. This common practice often transpires as a lifecycle management strategy that not only provides cost-effective solutions and supply chain continuity, but also provides patient benefits. Attend this webinar to hear industry expert, Christy Eatmon, discuss:

  • Evaluating regulatory and cost implications
  • Trends for switching
  • Release profile options
  • Supply chain requirements and lead times

Christy Eatmon
Global SME, Sterile Drug Products, Thermo Fisher Scientific

Christy Eatmon

Bio: Christy Eatmon supports the Global Sales and Business Development teams in providing technical support, designing strategies and supporting new business opportunities for Thermo Fisher Scientific’s sterile manufacturing business. Christy has more than 15 years of experience in the pharmaceutical industry with an emphasis on process engineering, product development, aseptic manufacturing and filling. She has working knowledge of all phases from drug discovery to sterile product commercial manufacturing with expertise in small and large molecule sterile formulation. Previously, Christy supported the Greenville, North Carolina, site as a Senior Principal Scientist in the Commercial Operations and Pharmaceutical Development Services areas.

Related Sites

Additional Resources